Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03230292 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Adult Patients With Chronic Plaque Psoriasis
A Phase 2 study, sponsored by UCB Biopharma SRL.
- Completed
- Registry status
- Phase 2
- Development phase
- 43
- Enrollment target
NCT03230292 is a Phase 2 study that has completed, run by UCB Biopharma SRL. The registered enrollment target is 43 participants.
The verdict
NCT03230292, a Phase 2 study, has completed, sponsored by UCB Biopharma SRL.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 43 participants
- Enrollment target
Study Summary
This is a study to assess the long-term safety, tolerability, and efficacy of bimekizumab.
Interventions
- DRUG Bimekizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2017-07-03 |
| Est. Completion | 2019-03-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03230292
The ClinicalTrials.gov registry entry for NCT03230292 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCB Biopharma SRL, which has 82 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Bimekizumab is the first listed.
NCT03230292 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03230292 about?
NCT03230292 is a clinical study titled "A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Adult Patients With Chronic Plaque Psoriasis". This is a study to assess the long-term safety, tolerability, and efficacy of bimekizumab.
What is the current status of trial NCT03230292?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 43 participants. The study started on 2017-07-03. Estimated completion is 2019-03-06.
What interventions are being tested in trial NCT03230292?
The interventions under investigation include: Bimekizumab (DRUG).
Who is sponsoring clinical trial NCT03230292?
This trial is sponsored by UCB Biopharma SRL, which has 82 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.